DBV Technologies S.A. – America (DBVT) Saw a New 52-Week Low

0
16

The company is trading down by 41.09%% since yesterday’s close of 48.07. It is currently trading at $28.32 which is quite a bit lower than $44.48, the stock’s 50 day moving average and impressively lower than the 200 day moving average of $39.50. The 50 day moving average was down by -36.33% whereas the 200 day moving average was down $-11.18 or -28.31%.

Investors are more bearish on shares of DBV Technologies S.A. – America if you take note of the change in short interest. The firm realized a rise in short interest from September 15, 2017 to September 29, 2017 of 31.32%. Short shares increased from 803,462 to 1,055,107 over that period. The days to cover decreased to 4.0 and the percentage of shorted shares is 0.02% as of September 29.

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product which is in Phase III clinical trials for the treatment of peanut allergies in children, adolescents, and adults. The company is also developing Viaskin Milk that is in Phase II clinical trials for the treatment of CMPA and milk-induced eosinophilic esophagitis; and Viaskin Egg, a pre-clinical stage product for the treatment of hen’s egg allergy. Its other earlier stage product development programs include a booster vaccine for pertussis, as well as treatments for Crohn’s disease and respiratory syncytial virus. DBV Technologies S.A. has collaboration with Nestlé Health Science to develop and commercialize a novel diagnostic test for pediatric milk allergy. The company was founded in 2002 and is headquartered in Montrouge, France..

Additionally, here are a few investment firms who have increased or decreased their stake in (DBVT). Janus Capital Management LLC trimmed its investment by selling 27,412 shares a decrease of 1.1%. Janus Capital Management LLC owns 2,507,217 shares worth $88,302,000. The value of the position overall is down by 0.9%. Gw&k Investment Management, LLC divested its stake by shedding 1,217 shares a decrease of 1.2% as of 09/30/2017. Gw&k Investment Management, LLC currently owns 99,666 shares valued at $4,230,000. The total value of its holdings increased 17.4%.

As of the end of the quarter Cutler Group LP had acquired a total of 2,000 shares growing its stake by 83.3%. The value of the investment in DBV Technologies S.A. – America went from $11,000 to $25,000 a change of 127.3% quarter over quarter. SIT Investment Associates Inc cut its position by shedding 700 shares a decrease of 3.6% in the quarter. SIT Investment Associates Inc claims 18,850 shares with a value of $800,000. The total value of its holdings increased 14.6%.

July 11 investment analysts at Morgan Stanley held the stock rating at “Overweight” but raised the price target to $67.00 from $59.00. On October 2 Citigroup made no change to the stock rating of “Buy” but raised the price expectation from $43.00 to $57.00.

On October 6 Morgan Stanley made no change to the company rating of “Overweight” and raised the price target to $72.00 from $67.00. October 23 investment analysts at Leerink Swann maintained a company rating of “Overweight” and lowered the price expectation from $56.00 to $30.00.

On October 23 Barclays maintained a stock rating of “Overweight” but moved down the price target from $58.00 to $30.00.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.